Preferred Label : Flumbatinib;
NCIt synonyms : 4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide; Flumatinib;
NCIt definition : An orally bioavailable tyrosine kinase inhibitor, with potential antineoplastic activity.
Upon administration, flumbatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived
growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit)
and forms of these proteins with certain point mutations. This results in the inhibition
of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the
proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion
protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome
positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute
myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor
tyrosine kinase essential to cell migration and the development of the microvasculature.
c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain
tumors, plays a key role in tumor cell survival, proliferation, and differentiation.;
UNII : R4009Y24AI;
InChIKey : BJCJYEYYYGBROF-UHFFFAOYSA-N;
CAS number : 895519-90-1;
Molecule name : HH-GV-678; HH GV 678;
Codes from synonyms : 38662;
Origin ID : C138991;
UMLS CUI : C4317329;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_salt_form
- is_free_acid_or_base_form_of
